Key result
Rapid haloperidol response is linked to lower plasma homovanillic acid concentrations at week 4.
Why the study?
What are the clinical and biochemical correlates of rapid neuroleptic response in male schizophrenic inpatients treated with haloperidol?
Observational (n=16)
What are the clinical and biochemical correlates of rapid neuroleptic response in male schizophrenic inpatients treated with haloperidol?
Rapid response to haloperidol in male schizophrenic patients is associated with lower plasma homovanillic acid concentrations at 4 weeks, but not with baseline demographics or symptom severity.
Answers are grounded in this paper and cite their sources.
Lower week-4 pHVA was associated with rapid haloperidol response in schizophrenia; hypothesis-generating for biomarker utility and requires prospective validation before clinical use.
Correlates of neuroleptic response latency were assessed in 16 male schizophrenic inpatients during 4 weeks of fixed dose (20 mg/day) haloperidol treatment. Rapid responders showed a mean 40% reduction in Brief Psychiatric Rating Scale (BPRS) positive symptom scores by day 10 of treatment. Rapid responders had significantly lower plasma homovanillic acid (pHVA) concentrations compared to non-rapid responders during week 4 of haloperidol treatment. However, rapid versus non-rapid responders did not differ with respect to demographics, baseline positive or negative BPRS symptom scores, performance on tests of neuropsychological function, or mean plasma haloperidol concentrations.
No takes yet. Share an insight, caveat, or question.
Petrie et al. (1990) conducted an observational in schizophrenia (n=16). Haloperidol vs. Non-rapid responders was evaluated on plasma homovanillic acid (pHVA) concentrations during week 4. Rapid responders to haloperidol treatment had significantly lower plasma homovanillic acid concentrations compared to non-rapid responders during week 4.
Synapse has enriched 10 related papers. Consider them for comparative context: